Literature DB >> 3120971

Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.

M Böttiger1, B Christenson, V Romanus, J Taranger, A Strandell.   

Abstract

In 1982 a two dose regimen was introduced in Sweden for the combined vaccination against measles, mumps, and rubella of children aged 18 months and 12 years. Since 1977 about half of the preschool children were vaccinated against measles annually, and since 1974 about 80% of 12 year old girls were vaccinated against rubella. During the period 1982 to 1985 90-93% of the eligible age cohorts of 18 month old children and 88-91% of the 12 year old children were immunised with the new combined vaccine. A study in 1982 of about 140 18 month old children who were nearly all seronegative before vaccination showed that 96%, 92%, and 99% seroconverted against measles, mumps, and rubella, respectively. A second study was carried out in 1983 of 247 12 year old children, of whom 11% lacked antibodies to measles, 27% to mumps, and 45% to rubella. This showed seroconversion in 82% and 80% against measles and mumps, respectively, and all children seroconverted against rubella. In the latest study in 1985 of 496 12 year olds 9% and 13% were seronegative against measles and mumps before vaccination, and 41% against rubella. Of these, 88% seroconverted to measles and 80% to mumps, and all converted to rubella when sera were tested by the haemolysis in gel method. After a neutralisation test against measles as well all children showed immunity to the disease. A low incidence of measles and declining figures for mumps and rubella were reported in 1984 to 1986. An outbreak of rubella during 1985 affected mainly boys in age cohorts in which only the girls had been vaccinated during the 1970s.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120971      PMCID: PMC1248321          DOI: 10.1136/bmj.295.6608.1264

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  8 in total

1.  Microneutralization test for the determination of mumps antibody in vero cells.

Authors:  M T Kenny; K L Albright; R P Sanderson
Journal:  Appl Microbiol       Date:  1970-09

2.  Vaccination against measles, mumps and rubella (MMR): a comparison between the antibody responses at the ages of 18 months and 12 years and between different methods of antibody titration.

Authors:  B Christenson; M Böttiger
Journal:  J Biol Stand       Date:  1985-04

Review 3.  Imported malaria: an uninvited guest.

Authors:  L J Bruce-Chwatt
Journal:  Br Med Bull       Date:  1982-05       Impact factor: 4.291

4.  Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren.

Authors:  M Böttiger; B Christenson; J Taranger; M Bergman
Journal:  Vaccine       Date:  1985-06       Impact factor: 3.641

5.  [Vaccination status in Swedish preschool children].

Authors:  V Romanus; R Jonsell; M Böttiger; A Alvin; G Sandzelius
Journal:  Lakartidningen       Date:  1982-08-25

6.  Persistence of rubella antibody 8-18 years after vaccination.

Authors:  S O'Shea; J M Best; J E Banatvala; W C Marshall; J A Dudgeon
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-07

7.  Further-attenuated measles vaccine: characteristics and use.

Authors:  S Krugman
Journal:  Rev Infect Dis       Date:  1983 May-Jun

8.  Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience.

Authors:  B Christenson; M Böttiger; L Heller
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06
  8 in total
  14 in total

Review 1.  Rubella in Europe.

Authors:  A Galazka
Journal:  Epidemiol Infect       Date:  1991-08       Impact factor: 2.451

2.  Prevention in family practice: Consensus statement from the front line.

Authors:  G Satenstein; J Lemelin; C Folkerson; K A Scott; W E Hogg
Journal:  Can Fam Physician       Date:  1991-10       Impact factor: 3.275

3.  Seroepidemiology of measles in Catalonia (Spain) 1985-1986.

Authors:  L Salleras; J Vidal; J Canela; M T Jimenez De Anta; T Pumarola; J J Coll; M L De La Puente; L Serra
Journal:  Eur J Epidemiol       Date:  1990-06       Impact factor: 8.082

4.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Mumps meningitis after mumps, measles, and rubella vaccination.

Authors:  J A Gray; S M Burns
Journal:  BMJ       Date:  1989-12-09

Review 6.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

7.  Idiopathic thrombocytopenic purpura and MMR vaccine.

Authors:  E Miller; P Waight; C P Farrington; N Andrews; J Stowe; B Taylor
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

8.  Measles control in Maputo, Mozambique, using a single dose of Schwarz vaccine at age 9 months.

Authors:  F T Cutts; O Monteiro; P Tabard; J Cliff
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

Review 9.  Rubella vaccination.

Authors:  J Forster
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

10.  A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.

Authors:  Gary S Marshall; Shelly D Senders; Julie Shepard; Jerry D Twiggs; Julie Gardner; Darcy Hille; Jonathan Hartzel; Rowan Valenzuela; Jon E Stek; Frans A Helmond
Journal:  Hum Vaccin Immunother       Date:  2016-05-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.